Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01996046

FDG PET/CT in Breast Cancer Bone Mets

Sponsor: University of Pennsylvania

View on ClinicalTrials.gov

Summary

This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.

Official title: 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

75

Start Date

2013-09

Completion Date

2026-07-31

Last Updated

2025-09-02

Healthy Volunteers

No

Interventions

OTHER

FDG PET/CT scan

\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy

Locations (1)

University of Pennsylvania Hospital

Philadelphia, Pennsylvania, United States